Golden Ten Data October 15|Canaccord Genuity has lowered the target price of BioNTech from $136 to $132, maintaining a "Buy" rating.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.